Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04400240
Other study ID # 00070647
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 1, 2018
Est. completion date December 31, 2019

Study information

Verified date May 2020
Source Medical University of South Carolina
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Care-coordination Approach to Learning Lupus Self-Management (CALLS) study was designed to examine whether modeling and reinforcement from a lay patient navigator/care coordinator improves disease self-management, indicators of disease activity, health related quality of life (HRQOL), and 30-day readmission in SLE inpatient admissions. We recruited 30 patients (~15 questionnaires and phone sessions and 15 questionnaires only) with active SLE upon hospital admittance at the Medical University of South Carolina (MUSC). The lay patient navigator/care coordinator was trained to deliver intervention content by twelve weekly telephone sessions carried out across the course of the study. All participants were assessed using validated measures of patient reported outcomes at baseline, mid-intervention (6 weeks post-enrollment), and immediately following the intervention (12 weeks post-enrollment). Outcomes for patients who agreed to phone sessions were compared with the outcomes of patients who opted to participate in questionnaires only. The study lasted 12 months, with recruitment and enrollment over 6 months, 3 months for intervention delivery and 3 months for data analysis.


Description:

Overview of Study Design. The Care-coordination Approach to Learning Lupus Self-Management (CALLS) study is a double arm, pre-post pilot designed to examine whether modeling and reinforcement from a lay patient navigator/care coordinator improves disease self-management, indicators of disease activity, health related quality of life (HRQOL), and 30-day readmission in SLE inpatient admissions. We will recruit 40 patients (20 questionnaires and phone sessions and 20 questionnaires only) with active SLE upon hospital admittance at the Medical University of South Carolina (MUSC). The lay patient navigator/care coordinator will be trained to deliver intervention content by twelve weekly telephone sessions carried out across the course of the study. All participants will be assessed using validated measures of patient reported outcomes at baseline, mid-intervention (6 weeks post-enrollment), and immediately following the intervention (12 weeks post-enrollment). Outcomes for patients who agree to phone sessions will be compared with the outcomes of patients who opt to participate in questionnaires only. The study will last 12 months with recruitment and enrollment over 6 months, 3 months for intervention delivery and 3 months for data analysis.

Study Population. The target population for this study will be SLE inpatient admissions at MUSC. There are approximately 35 SLE and Scleroderma hospital admissions each month, so it is expected that over a 3-month recruitment period, we will be able to recruit 40 participants (20 questionnaires and phone sessions and 20 questionnaires only).

Recruitment of Lay Patient Navigator/Care Coordinator The PI will identify a suitable lay patient navigator/care coordinator based on their maturity, emotional stability, and verbal communication skills. Suitable candidates will have at least a high school diploma or equivalency with at least one year of patient care experience in a health care facility; or a Certified Nursing Assistant; or successful completion of a Nursing Assistant or Medical Assistant course at an accredited institution or equivalent training; or EMT or Paramedic certification; or a Bachelor's degree. They will possess the ability to understand and implement a variety of detailed instructions in the execution of therapeutic procedures and the ability to make accurate physical observation of patients.

Recruitment of SLE patients Admitted SLE patients will be referred by their physician for participation in the study, who will provide a letter that will explain the study and provide participants a number to call if they have questions or concerns prior to agreeing to participate. Participants who indicate interest in the study will be immediately screened for eligibility, and if eligibility criteria are met, informed consent will be obtained. Once a patient has been consented, they will be randomized to membership in one of the two study arms. assigned to the intervention (complete questionnaires and phone sessions) or control (complete questionnaires only) arm, and the rest of the recruitment visit will include baseline self-report assessments and scheduling of phone sessions (if applicable).

Phone sessions: The CALLS program will focus on enhancing the health of SLE patients, with emphasis on patient empowerment and promoting proactive participation in health care. Recruitment and enrollment will occur on a rolling basis, and the program will consist of 12 weeks of service delivery that will include one standard educational session by telephone or in-person meeting every week. The weekly educational session will be generally structured in three parts: introduction, structured education, and problem solving. Weekly content will be adapted from the twelve modules of the Peer Approaches to Lupus Self-management (PALS) study, and further tailored according to prominent barriers to care in the scientific literature. Content will include: 1) Medication adherence; 2) Communication with provider; 3) Patient engagement; 4) Recognizing and treating depression; 5) Overcoming socioeconomic barriers; 6) Social Support network; 7) Appointment/ Lab adherence; and 8) Transportation. The lay patient navigator/care coordinator will respond to individual patient needs by tailoring intervention content to personal requirements and facilitating care coordination and will be able to address insurance, financial, and logistical issues (e.g., transportation, appointment scheduling, child or elder care), while providing understandable health education that may lessen fears of SLE diagnosis and treatment. Lay patient navigator/care coordinator activities will be guided by frequent self-report assessments, which will help to identify patient concerns across multiple domains, triage patients to appropriate resources, and ultimately overcome barriers to health care. The lay patient navigator/care coordinator can use baseline data collected prior to phone sessions to describe preliminary patient themes (i.e., disease activity and damage, depression, medication adherence, communication with provider, patient engagement) and subsequent assessments can be used to track progress.

Data Collection Schedule. Study questionnaires were carefully chosen based on available evidence of previous validation and their ability to measure key elements of the study aims. The primary method of data collection will be face-to-face interview. All study visits will take place in an MUSC affiliated hospital, the Research Nexus or comparable private location on the campus of MUSC. Indicators of medication adherence will be extracted from the electronic medical records. Financial data will be extracted from the research data warehouse for historical and patient-specific data for cost effectiveness. The MUSC REDCap system will be used for data management.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date December 31, 2019
Est. primary completion date December 31, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Hospital admission for SLE-related issue;

2. clinical diagnosis of systemic lupus erythematosus (SLE) from a physician;

3. 18 years of age or older;

4. able to provide informed consent and take part in ongoing assessment/evaluation activities (self-reported questionnaires);

5. able to commit to duration of study (3 months);

6. able to communicate in English; and

7. have an active phone line (landline or cell phone) for the duration of the study, if agreeing to phone sessions with the lay patient navigator/care coordinator.

Exclusion Criteria:

1. cognitive impairment;

2. acute decompensation of chronic conditions precluding participation;

3. conditions that preclude participation in assessments (e.g. blindness or deafness); and

4. terminal illness or life expectancy less than 6 months as evaluated by physician.

Study Design


Intervention

Behavioral:
CALLS
The CALLS program will consist of 12 weeks of service delivery that will include one standard educational session by telephone or in-person meeting every week. The weekly educational session will be generally structured in three parts: introduction, structured education, and problem solving. Weekly content will be adapted from the twelve modules of the Peer Approaches to Lupus Self-management (PALS) study, and further tailored according to prominent barriers to care in the scientific literature. Content will include: 1) Medication adherence; 2) Communication with provider; 3) Patient engagement; 4) Recognizing and treating depression; 5) Overcoming socioeconomic barriers; 6) Social Support network; 7) Appointment/ Lab adherence; and 8) Transportation.

Locations

Country Name City State
United States Medical University of South Carolina Charleston South Carolina

Sponsors (1)

Lead Sponsor Collaborator
Medical University of South Carolina

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Self-management measured using the Patient Activation Measure (PAM) The Patient Activation Measure (PAM) assesses an individual's knowledge, skill, and confidence for managing their health and healthcare. Individuals who measure high on this assessment typically understand the importance of taking a proactive role in managing their health and have the skills and confidence to do so. The PAM survey measures patients on a 0-100 scale and can segment patients into one of four activation levels along an empirically derived continuum, including "Believes Active Role Important", "Confidence and Knowledge to Take Action", "Taking Action", and "Staying Course Under Stress". Each activation level reveals insight into an array of health-related characteristics, including attitudes, motivators, behaviors, and outcomes. Baseline to post-intervention, at 12 weeks
Primary Satisfaction in Quality of Life as assessed by the LUP-QOL (Lupus Quality of Life Questionnaire) Quality of life will be assessed by using The LUP-QOL (Lupus Quality of Life Questionnaire), which assesses areas of the participant's life that may be affected by lupus. The score ranges from 0-100. A score of '0' indicates the lowest quality of life, and a score of 100 indicates the best quality of life. Baseline to post-intervention, at 12 weeks
Secondary 30-day readmission Change in cost due to readmission. Costs will include total charges associated with any healthcare encounters at the Medical University of South Carolina. Baseline to post-intervention, at 12 weeks
See also
  Status Clinical Trial Phase
Terminated NCT03843125 - A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE) Phase 3
Recruiting NCT05698173 - Systemic Lupus Erythematosus and Accelerated Aging N/A
Active, not recruiting NCT01649765 - Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy Phase 2
Recruiting NCT05704153 - Modelling and Control of Non-invasive Vagus Nerve Stimulation for Autoimmune Diseases (1A) N/A
Completed NCT05048238 - Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus Phase 1
Recruiting NCT06056778 - The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)
Completed NCT04358302 - Individual Patient Exposure and Response in Pediatric Lupus N/A
Completed NCT03802578 - The Impact of Exercise on Hand Function, Daily Activities Performance and Quality of Life of SLE' Patients N/A
Completed NCT02554019 - Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus Phase 2
Recruiting NCT04835883 - Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients Phase 2
Terminated NCT02665364 - Phase IIb Study of IFN-K in Systemic Lupus Erythematosus Phase 2
Completed NCT00278538 - Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus Phase 2
Completed NCT00069342 - Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases
Completed NCT03252587 - An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus Phase 2
Terminated NCT02066311 - Nelfinavir in Systemic Lupus Erythematosus Phase 2
Recruiting NCT01892748 - Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus. N/A
Terminated NCT01689025 - An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE) Phase 1
Unknown status NCT01712529 - Physical Exercise, Endothelial Function and Progenitor Endothelial Cells in Systemic Lupus Erythematosus Patients N/A
Completed NCT01475149 - Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE) N/A
Completed NCT00962832 - A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus Phase 2